A newly released Drug Discovery Informatics Market analysis report by Future Market Insights reveals that global sales of the Drug Discovery Informatics Market in 2022 were held at US$ 2.9 billion. With a CAGR of 14.4% from 2023 to 2033, the market is projected to reach a valuation of US$ 12.5 billion by 2033. Discovery Informatics is expected to be the highest revenue-generating segment, projected to grow at a CAGR of over 15% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Drug Discovery Informatics Market (2022) | US$ 2.9 billion |
| Global Drug Discovery Informatics Market (2033) | US$ 12.5 billion |
| Global Drug Discovery Informatics Market CAGR (2023 to 2033) | 14.4% |
| The USA Drug Discovery Informatics Market (2033) | US$ 4.1 million |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Drug Discovery Informatics Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value of the Drug Discovery Informatics Market increased at around 12.8% CAGR.
Drug Discovery Informatics supports precision medicine, which entails improving the potency of medical care. It improves the effectiveness of Drug Discovery Informatics for particular patient groups based on genetic or molecular profiling.
The growing focus on precision medicine, as well as technological advancements that have resulted in enhanced data storage, management, processing, and analysis, are driving the market. Simultaneously, data collection is critical since new gene sequencing and molecular profiling approaches have dramatically expanded the quantity of data accessible.
Discovery informatics makes the process of discovering and developing novel medications more efficient and streamlined. When compared to the traditional procedure, the time and cost of drug discovery are dramatically reduced.
Committing mistakes in the field of discovery informatics can be very expensive since billions of dollars are invested in the production of each active drug. Such mistakes can be avoided with analytics, which is propelling the industry's growth.
A number of factors such as an increase in research spending on informatics by the pharmaceutical and biotechnology industries drive the global market. Other factors include the emerging demand and abutment for rare disease and orphan drug research combined with increased attention on drug discovery using informatics software.
The rising amount of money spent on informatics research by biotechnology and pharmaceutical businesses is one of the most important factors driving the growth and demand for the Drug Discovery Informatics industry.
Furthermore, the growing need for and support for rare disease and orphan drug research, as well as a growing emphasis on drug discovery using informatics software, will propel the global market forward throughout the forecast period.
Furthermore, another factor fuelling the expansion of the Drug Discovery Informatics business is a diverse set of tools for data gathering, processing, and visualization. Additionally, regional businesses are focusing on the collaboration of research and initiatives. The surge in Healthcare IT industries, the demand for innovative pharmaceuticals in a faster time frame, and infrastructure costs contribute to informatics research's advancement.
Covid-19 has fuelled the rise of the Drug Discovery Informatics industry. Biopharmaceutical firms are investing significant capital toward developing the SARS-COV-2 vaccines. Researchers are evaluating both new and current medications to find treatments to treat the condition, which is propelling the market forward.
A key factor boosting the growth of the market is the emergence of cloud-based technology and new analytics. Cloud computing allows for low-cost storage, processing, and analysis of massive datasets. Faster and better scientific research results from the use of new computers and infrastructural technology.
Cloud computing offers the ability to speed up fundamental research efforts. Another significant factor projected to boost growth in the market is pharmaceutical firms' increasing migration from traditional to data-driven technologies. However, the market for Drug Discovery Informatics can be hampered by costly informatics software price and setup costs, as well as a lack of experienced resources.
Principal Consultant
North America was the largest contributor to the global Drug Discovery Informatics Market in 2022. The regional market will also dominate in the forthcoming years due to the high occurrence rates of various infectious and cancer diseases, as well as the rapid expansion of next-generation sequencing and chemical laboratories.
With the upgrades in the research tools and increasing clinical studies in the Asia Pacific, a similar growth trajectory in the region can be expected. The presence of the pharma nanotechnology sector as well as ongoing software research in the region is also driving growth.
By the end of 2033, the United States is expected to account for the largest market of US$ 4.1 billion. It previously grew at a significant CAGR of 12.3% from 2015 to 2022 and is now expected to grow at a CAGR of 14.4% over the forecasted period. A growing emphasis on data-driven solutions by biotech and pharmaceutical companies is one of the factors driving the Drug Discovery Informatics market in the area.
The market in the United Kingdom is expected to reach a valuation of US$ 669 million by 2033, growing at a CAGR of 16% from 2023 to 2033. The market is projected to gross an absolute dollar opportunity of US$ 514 million during the forecast period.
In Japan, the market is expected to reach a valuation of US$ 731 million by 2033. During the forecast period, the market in the country is expected to garner an absolute dollar opportunity of US$ 597 million, growing at a CAGR of 18.7%.
The market in South Korea is projected to grow at a CAGR of 12.8% during 2023 to 2033. During this period, the market is projected to witness an absolute dollar opportunity of US$ 194 million and reach US$ 275 million by 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Discovery Informatics commanded the largest revenue share of the market, and grew at a CAGR of nearly 13.7% from 2018 to 22 and is forecasted to grow at a CAGR of 15.4% throughout the forecasted period.
The substantial share of this market may be due to the rising use of sequencing analysis for novel drug entities and the convenience of managing data from many sources and domains. Precision medicine refers to medical treatment that is tailored to a patient's genetic and molecular profile. Companies have begun to provide discovery informatics solutions in order to use analytics to speed up drug discovery. In addition, governments in several underdeveloped countries are supporting the use of bioinformatics to speed up the development of new medicines.
Sequence Analysis Platforms commanded the largest revenue in this regard and grew at a CAGR of nearly 14.1% from 2018 to 22 and is forecasted to grow at a CAGR of 17% throughout the forecasted period.
Over the projection period, this category will maintain its dominance. Bioinformatics tools are commonly used to create primary and secondary databases of nucleic acid, protein, and other biomolecular sequences. Mining and storage of genome sequencing data are done using informatics tools to discover genes and target proteins, which will aid in the creation of novel medications. Furthermore, fundamental drug discovery research necessitates the use of several databases as well as sequence analysis tools. The advent of new and improved software is also helping to develop the market.
Some of the key companies in the drug discovery informatics market include Certara, Boehringer Ingelheim International GmbH, Infosys Ltd., Charles River Laboratories, Collaborative Drug Discovery, Inc., Eurofins DiscoverX Products, Jubilant Biosys, Selvita, Novo Informatics Pvt. Ltd., ChemAxon Ltd., Albany Molecular Research Inc., Oracle, Accenture, Agilent Technologies, Inc., and Illumina, Inc.
Some of the recent developments of key Drug Discovery Informatics providers are as follows:
The market is expected to reach US$ 12.5 billion by 2033.
Certara and Infosys Ltd. are the leading market players.
The market registered a CAGR of 12.8% from 2018 to 2022.
The emergence of cloud-based technology is estimated to boost the market prospects.
The United States is predicted to expand at a CAGR of 14.4% through 2033.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technique
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) Analysis By Technique, 2018 to 2022
5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Technique, 2023 to 2033
5.3.1. Discovery Informatics
5.3.1.1. Identification, Validation, & Assay Development Informatics
5.3.1.2. Lead Generation
5.3.1.3. Enzymes
5.3.1.4. Other Cleanings
5.3.2. Development Informatics
5.3.2.1. Lead Optimization
5.3.2.2. FHD Preparation
5.3.2.3. Phase IA
5.3.2.4. Phase IB/2
5.4. Y-o-Y Growth Trend Analysis By Technique, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Technique, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) Analysis By Mode, 2018 to 2022
6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Mode, 2023 to 2033
6.3.1. Outsourced
6.3.2. In-house
6.4. Y-o-Y Growth Trend Analysis By Mode, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Mode, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ million) Analysis By Services, 2018 to 2022
7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Services, 2023 to 2033
7.3.1. Sequence Analysis Platforms
7.3.2. Molecular Modeling
7.3.3. Docking
7.3.4. Clinical Trial Data Management
7.3.5. Other Services
7.4. Y-o-Y Growth Trend Analysis By Services, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Services, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The USA
9.2.1.2. Canada
9.2.2. By Technique
9.2.3. By Mode
9.2.4. By Services
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Technique
9.3.3. By Mode
9.3.4. By Services
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Technique
10.2.3. By Mode
10.2.4. By Services
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Technique
10.3.3. By Mode
10.3.4. By Services
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. The United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Russia
11.2.1.7. Rest of Europe
11.2.2. By Technique
11.2.3. By Mode
11.2.4. By Services
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Technique
11.3.3. By Mode
11.3.4. By Services
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. India
12.2.1.4. South Korea
12.2.1.5. Australia
12.2.1.6. Rest of APAC
12.2.2. By Technique
12.2.3. By Mode
12.2.4. By Services
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Technique
12.3.3. By Mode
12.3.4. By Services
12.4. Key Takeaways
13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. South Africa
13.2.1.2. Saudi Arabia
13.2.1.3. UAE
13.2.1.4. Israel
13.2.1.5. Rest of Middle East and Africa (MEA)
13.2.2. By Technique
13.2.3. By Mode
13.2.4. By Services
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Technique
13.3.3. By Mode
13.3.4. By Services
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. The USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Technique
14.1.2.2. By Mode
14.1.2.3. By Services
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Technique
14.2.2.2. By Mode
14.2.2.3. By Services
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Technique
14.3.2.2. By Mode
14.3.2.3. By Services
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Technique
14.4.2.2. By Mode
14.4.2.3. By Services
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Technique
14.5.2.2. By Mode
14.5.2.3. By Services
14.6. The United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Technique
14.6.2.2. By Mode
14.6.2.3. By Services
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Technique
14.7.2.2. By Mode
14.7.2.3. By Services
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Technique
14.8.2.2. By Mode
14.8.2.3. By Services
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Technique
14.9.2.2. By Mode
14.9.2.3. By Services
14.10. Russia
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Technique
14.10.2.2. By Mode
14.10.2.3. By Services
14.11. China
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Technique
14.11.2.2. By Mode
14.11.2.3. By Services
14.12. Japan
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Technique
14.12.2.2. By Mode
14.12.2.3. By Services
14.13. India
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Technique
14.13.2.2. By Mode
14.13.2.3. By Services
14.14. South Korea
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Technique
14.14.2.2. By Mode
14.14.2.3. By Services
14.15. Australia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Technique
14.15.2.2. By Mode
14.15.2.3. By Services
14.16. South Africa
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Technique
14.16.2.2. By Mode
14.16.2.3. By Services
14.17. Saudi Arabia
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Technique
14.17.2.2. By Mode
14.17.2.3. By Services
14.18. UAE
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Technique
14.18.2.2. By Mode
14.18.2.3. By Services
14.19. Israel
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Technique
14.19.2.2. By Mode
14.19.2.3. By Services
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Technique
15.3.3. By Mode
15.3.4. By Services
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. PerkinElmer, Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Thermo Fisher Scientific, Inc.
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Certara, L.P.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Novo Informatics
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Collaborative Drug Discovery Inc.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Jubilant Life Sciences Limited
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Selvita
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Charles River Laboratories International, Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. ChemBridge Corporation
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Albany Molecular Research Inc.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.11. GVK Biosciences
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.12. Agilent Technologies, Inc.
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Drug Discovery Informatics Market
